Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02394054 · ClinicalTrials.gov registry record · Early Phase 1
Vasopressin and the Social Brain
A Early Phase 1 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 84
- Enrollment target
NCT02394054 is a Early Phase 1 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 84 participants.
The verdict
NCT02394054, a Early Phase 1 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 84 participants
- Enrollment target
Study Summary
It has long been established that interpersonal relationships can have a profound impact on health and well-being. Yet, the investigators are still learning about the complex biological processes that contribute to positive social interactions and the ability to develop and maintain social relationships. Recent research has begun to focus on vasopressin, a neuropeptide that is naturally produced in the hypothalamus, because administration of this neuropeptide has been associated with empathy, cooperation, memory of social stimuli (e.g., faces), and brain activity in neural regions associated with social and emotional processes. To date, several aspects of vasopressin's effects on social behavior have been unexplored. As such, the overarching goal of this project is to examine the effects of intranasal vasopressin on several tasks involving learning and social processes. In addition, the investigators will explore associated neural activity through functional magnetic resonance imaging (fMRI). Results from the study will inform our understanding of the neurobiology of socioemotional processes. The investigators hypothesize that compared to placebo, vasopressin will improve deception detection, increase empathy and altruism, enhance responses to photo stimuli of primary caregivers, and improve learning when the subject has a prosocial goal of teaching another person. These effects will manifest in behavioral and neural activity. It is also hypothesized that main effects will not be found for vasopressin, but rather, analyses of relevant moderators will elucidate these findings.
Interventions
- DRUG Intranasal placebo
- DRUG Intranasal vasopressin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2015-01 |
| Est. Completion | 2016-07 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02394054
The ClinicalTrials.gov registry entry for NCT02394054 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Intranasal placebo is the first listed.
NCT02394054 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02394054 about?
NCT02394054 is a clinical study titled "Vasopressin and the Social Brain". It has long been established that interpersonal relationships can have a profound impact on health and well-being. Yet, the investigators are still learning about the complex biological processes that contribute to positive social interactions and the ability to develop and maintain social relations...
What is the current status of trial NCT02394054?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 84 participants. The study started on 2015-01. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02394054?
The interventions under investigation include: Intranasal placebo (DRUG), Intranasal vasopressin (DRUG).
Who is sponsoring clinical trial NCT02394054?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.